Bayshore Pharmaceuticals Adds Three New ANDA Approved Products
16 November 2021 - - US-based generic pharmaceuticals sales and distribution company Bayshore Pharmaceuticals, LLC has added three new FDA-approved products to their portfolio, the company said.

Metolazone Tablets USP, 2.5mg, 5mg and 10 mg, is the generic equivalent of Zaroxolyn Tablets. It is available by prescription only and is indicated for the treatment of high blood pressure and fluid retention.

Etodolac Immediate Release Tablets USP, 400 mg and 500 mg, is the generic equivalent of Lodine Tablets. Etodolac is a nonsteroidal anti-inflammatory drug and only available by prescription.

Ketotifen Fumarate Ophthalmic Solution, 0.035% (OTC and RX) is the generic equivalent of Zaditor.

It is an antihistamine that is indicated for the treatment of itchy eyes. Ketotifen is Bayshore Pharmaceutical's first ANDA approved product that is available by prescription or as an OTC in the Bayshore Label.

Bayshore Pharmaceuticals, LLC was established in 2011 in the centrally located area of Short Hills, NJ.

As a full-service Sales and Distribution company focusing on FDA-approved generic pharmaceuticals, Bayshore used its extensive knowledge and experience in global API and Finished Dosage form manufacturing to differentiate itself from other Generic Pharmaceutical Sales and Marketing organizations.

In addition to developing its wholly-owned portfolio of generic products, Bayshore utilized its longstanding industry relationships to augment its business by marketing other pharma manufacturer's ANDA products under the same Bayshore label.